SARS-CoV2 microarray
Introducing SARS-CoV-2 HuProt™: The Novel Coronavirus Microarray
IDStartEndSequence
S1-1112MFVFLVLLPLVS
S1-2718LLPLVSSQCVNL
S1-31324SQCVNLTTRTQL
S1-41930TTRTQLPPAYTN
S1-52536PPAYTNSFTRGV
S1-63142SFTRGVYYPDKV
S1-73748YYPDKVFRSSVL
S1-84354FRSSVLHSTQDL
S1-94960HSTQDLFLPFFS
S1-105566FLPFFSNVTWFH
S1-116172NVTWFHAIHVSG
S1-126778AIHVSGTNGTKR
S1-137384TNGTKRFDNPVL
S1-147990FDNPVLPFNDGV
S1-158596PFNDGVYFASTE
S1-1691102YFASTEKSNIIR
S1-1797108KSNIIRGWIFGT
S1-18103114GWIFGTTLDSKT
S1-19109120TLDSKTQSLLIV
S1-20115126QSLLIVNNATNV
S1-21121132NNATNVVIKVCE
S1-22127138VIKVCEFQFCND
S1-23133144FQFCNDPFLGVY
S1-24139150PFLGVYYHKNNK
S1-25145156YHKNNKSWMESE
S1-26151162SWMESEFRVYSS
S1-27157168FRVYSSANNCTF
S1-28163174ANNCTFEYVSQP
S1-29169180EYVSQPFLMDLE
S1-30175186FLMDLEGKQGNF
S1-31181192GKQGNFKNLREF
S1-32187198KNLREFVFKNID
S1-33193204VFKNIDGYFKIY
S1-34199210GYFKIYSKHTPI
S1-35205216SKHTPINLVRDL
S1-36211222NLVRDLPQGFSA
S1-37217228PQGFSALEPLVD
S1-38223234LEPLVDLPIGIN
S1-39229240LPIGINITRFQT
S1-40235246ITRFQTLLALHR
S1-41241252LLALHRSYLTPG
S1-42247258SYLTPGDSSSGW
S1-43253264DSSSGWTAGAAA
S1-44259270TAGAAAYYVGYL
S1-45265276YYVGYLQPRTFL
S1-46271282QPRTFLLKYNEN
S1-47277288LKYNENGTITDA
S1-48283294GTITDAVDCALD
S1-49289300VDCALDPLSETK
S1-50295306PLSETKCTLKSF
S1-51301312CTLKSFTVEKGI
S1-52307318TVEKGIYQTSNF
S1-53313324YQTSNFRVQPTE
S1-54319330RVQPTESIVRFP
S1-55325336SIVRFPNITNLC
S1-56331342NITNLCPFGEVF
S1-57337348PFGEVFNATRFA
S1-58343354NATRFASVYAWN
S1-59349360SVYAWNRKRISN
S1-60355366RKRISNCVADYS
S1-61361372CVADYSVLYNSA
S1-62367378VLYNSASFSTFK
S1-63373384SFSTFKCYGVSP
S1-64379390CYGVSPTKLNDL
S1-65385396TKLNDLCFTNVY
S1-66391402CFTNVYADSFVI
S1-67397408ADSFVIRGDEVR
S1-68403414RGDEVRQIAPGQ
S1-69409420QIAPGQTGKIAD
S1-70415426TGKIADYNYKLP
S1-71421432YNYKLPDDFTGC
S1-72427438DDFTGCVIAWNS
S1-73433444VIAWNSNNLDSK
S1-74439450NNLDSKVGGNYN
S1-75445456VGGNYNYLYRLF
S1-76451462YLYRLFRKSNLK
S1-77457468RKSNLKPFERDI
S1-78463474PFERDISTEIYQ
S1-79469480STEIYQAGSTPC
S1-80475486AGSTPCNGVEGF
S1-81481492NGVEGFNCYFPL
S1-82487498NCYFPLQSYGFQ
S1-83493504QSYGFQPTNGVG
S1-84499510PTNGVGYQPYRV
S1-85505516YQPYRVVVLSFE
S1-86511522VVLSFELLHAPA
S1-87517528LLHAPATVCGPK
S1-88523534TVCGPKKSTNLV
S1-89529540KSTNLVKNKCVN
S1-90535546KNKCVNFNFNGL
S1-91541552FNFNGLTGTGVL
S1-92547558TGTGVLTESNKK
S1-93553564TESNKKFLPFQQ
S1-94559570FLPFQQFGRDIA
S1-95565576FGRDIADTTDAV
S1-96571582DTTDAVRDPQTL
S1-97577588RDPQTLEILDIT
S1-98583594EILDITPCSFGG
S1-99589600PCSFGGVSVITP
S1-100595606VSVITPGTNTSN
S1-101601612GTNTSNQVAVLY
S1-102607618QVAVLYQDVNCT
S1-103613624QDVNCTEVPVAI
S1-104619630EVPVAIHADQLT
S1-105625636HADQLTPTWRVY
S1-106631642PTWRVYSTGSNV
IDStartEndSequence
S1-107637648STGSNVFQTRAG
S1-108643654FQTRAGCLIGAE
S1-109649660CLIGAEHVNNSY
S1-110655666HVNNSYECDIPI
S1-111661672ECDIPIGAGICA
S1-112667678GAGICASYQTQT
S1-113673684SYQTQTNSPRRA
S1-114679685NSPRRARGGGGS
S2-1686697SVASQSIIAYTM
S2-2692703IIAYTMSLGAEN
S2-3698709SLGAENSVAYSN
S2-4704715SVAYSNNSIAIP
S2-5710721NSIAIPTNFTIS
S2-6716727TNFTISVTTEIL
S2-7722733VTTEILPVSMTK
S2-8728739PVSMTKTSVDCT
S2-9734745TSVDCTMYICGD
S2-10740751MYICGDSTECSN
S2-11746757STECSNLLLQYG
S2-12752763LLLQYGSFCTQL
S2-13758769SFCTQLNRALTG
S2-14764775NRALTGIAVEQD
S2-15770781IAVEQDKNTQEV
S2-16776787KNTQEVFAQVKQ
S2-17782793FAQVKQIYKTPP
S2-18788799IYKTPPIKDFGG
S2-19794805IKDFGGFNFSQI
S2-20800811FNFSQILPDPSK
S2-21806817LPDPSKPSKRSF
S2-22812823PSKRSFIEDLLF
S2-23818829IEDLLFNKVTLA
S2-24824835NKVTLADAGFIK
S2-25830841DAGFIKQYGDCL
S2-26836847QYGDCLGDIAAR
S2-27842853GDIAARDLICAQ
S2-28848859DLICAQKFNGLT
S2-29854865KFNGLTVLPPLL
S2-30860871VLPPLLTDEMIA
S2-31866877TDEMIAQYTSAL
S2-32872883QYTSALLAGTIT
S2-33878889LAGTITSGWTFG
S2-34884895SGWTFGAGAALQ
S2-35890901AGAALQIPFAMQ
S2-36896907IPFAMQMAYRFN
S2-37902913MAYRFNGIGVTQ
S2-38908919GIGVTQNVLYEN
S2-39914925NVLYENQKLIAN
S2-40920931QKLIANQFNSAI
S2-41926937QFNSAIGKIQDS
S2-42932943GKIQDSLSSTAS
S2-43938949LSSTASALGKLQ
S2-44944955ALGKLQDVVNQN
S2-45950961DVVNQNAQALNT
S2-46956967AQALNTLVKQLS
S2-47962973LVKQLSSNFGAI
S2-48968979SNFGAISSVLND
S2-49974985SSVLNDILSRLD
S2-50980991ILSRLDKVEAEV
S2-51986997KVEAEVQIDRLI
S2-529921003QIDRLITGRLQS
S2-539981009TGRLQSLQTYVT
S2-5410041015LQTYVTQQLIRA
S2-5510101021QQLIRAAEIRAS
S2-5610161027AEIRASANLAAT
S2-5710221033ANLAATKMSECV
S2-5810281039KMSECVLGQSKR
S2-5910341045LGQSKRVDFCGK
S2-6010401051VDFCGKGYHLMS
S2-6110461057GYHLMSFPQSAP
S2-6210521063FPQSAPHGVVFL
S2-6310581069HGVVFLHVTYVP
S2-6410641075HVTYVPAQEKNF
S2-6510701081AQEKNFTTAPAI
S2-6610761087TTAPAICHDGKA
S2-6710821093CHDGKAHFPREG
S2-6810881099HFPREGVFVSNG
S2-6910941105VFVSNGTHWFVT
S2-7011001111THWFVTQRNFYE
S2-7111061117QRNFYEPQIITT
S2-7211121123PQIITTDNTFVS
S2-7311181129DNTFVSGNCDVV
S2-7411241135GNCDVVIGIVNN
S2-7511301141IGIVNNTVYDPL
S2-7611361147TVYDPLQPELDS
S2-7711421153QPELDSFKEELD
S2-7811481159FKEELDKYFKNH
S2-7911541165KYFKNHTSPDVD
S2-8011601171TSPDVDLGDISG
S2-8111661177LGDISGINASVV
S2-8211721183INASVVNIQKEI
S2-8311781189NIQKEIDRLNEV
S2-8411841195DRLNEVAKNLNE
S2-8511901201AKNLNESLIDLQ
S2-8611961207SLIDLQELGKYE
S2-8712021213ELGKYEQYIKWP
S2-8812081219QYIKWPWYIWLG
S2-8912141225WYIWLGFIAGLI
S2-9012201231FIAGLIAIVMVT
S2-9112261237AIVMVTIMLCCM
S2-9212321243IMLCCMTSCCSC
S2-9312381249TSCCSCLKGCCS
S2-9412441255LKGCCSCGSCCK
S2-9512501261CGSCCKFDEDDS
S2-9612561267FDEDDSEPVLKG
S2-9712621273EPVLKGVKLHYT

All of our futures now depend on the human body’s ability to make antibodies to SARS-CoV-2, the virus that causes pandemic COVID-19 disease. And while it is now clear that recovered patients make protective antibodies against the disease – surprisingly it is the sickest patients making the most anti-SARS-CoV2 IgG antibodies [1].

The question is…why?

To help researchers answer this urgent question CDI Labs has created SARS-CoV-2 HuProt™: The Human Proteome Microarray with SARS-CoV-2 proteins. This new product combines >21,000 autologous human proteins with the S1 ACE2-receptor-binding spike & nucleocapsid from the virus that causes pandemic COVID-19 disease. With SARS-CoV-2 HuProt™, researchers can finally discover new antigen-specific immune responses that accompany different features of SARS-CoV-2 disease progression, clinical trial treatment response, and vaccine development.

Contact

Fields marked with an * are required
First Name
Last Name
Company or Institution
Email
Brief Project Description:

Why might human proteome microarrays with SARS-CoV-2 data be so important? There is evidence that cytokine release syndrome – similar to that seen in severe side effects of cancer immunotherapies – is involved in fatal COVID-19 cases [2]. CDI Labs collaborators at NYU have already demonstrated that similar side effects to cancer immunotherapies can be predicted by autoantibody signatures using HuProt™ arrays [3]. We made SARS-CoV-2 HuProt™ because we believe similar pre-existing autoantibody signatures may determine those most at risk for COVID-19 disease, may play a role in fatal cases, and can help guide clinical studies of COVID-19 treatments and vaccines. We think it’s time to Be Specific™ about COVID-19.

More about SARS-CoV-2 and pandemic COVID-19 disease:

Outbreak of the novel coronavirus (SARS-CoV-2) began in Wuhan China in late 2019 [4]. Novel coronavirus disease (COVID-19) is the symptomatic presentation of SARS-CoV-2 and presents with a diverse set of systemic and respiratory disorders including fever, cough, sore throat, fatigue, pneumonia with ground-glass opacities, acute cardiac injury, and respiratory distress [5]. Patients, particularly older men and people with underlying inflammatory conditions such as obesity, cardiovascular disease, COPD, and diabetes, are at higher risk of severe COVID-19 and death [6]. However, it is estimated that as many as 86% of SARS-CoV-2 infections are asymptomatic and do not result in COVID disease [7]. The particular reasons for this likely lie in the underlying immunologic response of the infected patients – but the reasons for this remain unclear. With SARS-CoV-2 HuProt™ Microarrays – these questions can now be answered.

More about SARS-CoV-2 HuProt™ Microarrays and Array Analysis Services:

SARS-CoV-2 HuProt™ Microarrays are available for direct purchase or an all-inclusive service. These arrays contain >21,000 full-length human proteins + the most important two SARS-CoV-2 proteins and is the most powerful tool ever created for mapping antigen-specific immunity. HuProt™ enables multi-isotype serum profiling of antibodies against three-dimensional antigens with a quantitative readout. It’s also useful for testing monoclonal antibodies, proteins, DNA, RNA, and even some small molecules.

The two SARS-CoV-2 proteins on these arrays are:

SARS-CoV-2 S1 Receptor-Binding Domain: This S1 ACE2 receptor binding spike is essential for entry of the novel coronavirus into human cells. Our S1 matches the sequence published here [8], is expressed in human cells, & has confirmed binding to ACE2.

SARS-CoV-2 Nucleocapsid: The nucleocapsid is the most abundant protein of a coronavirus. This version is purified from E.coli.

1. Jiang, H. et al. Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. https://www.medrxiv.org/content/10.1101/2020.03.20.20039495v1.
2. SITC Statement on anti-IL-6/IL-6R for COVID-19.
3. Gowen, M. F. et al. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. Journal of Translational Medicine 16, (2018).
4. Zhou, P. et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. https://www.biorxiv.org/content/10.1101/2020.01.22.914952v2.
5. Rothan, H. A. & Byrareddy, S. N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 102433 (2020) doi:10.1016/j.jaut.2020.102433.
6. Banerjee, A. Estimating excess 1- year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults. 23.
7. Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science eabb3221 (2020) doi:10.1126/science.abb3221.
8. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J Virol 94, e00127-20, /jvi/94/7/JVI.00127-20.atom (2020).